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PMH11
RETROSPECTIVE ECONOMIC EVALUATION OF 
MIRTAZAPINE, VENLAFAXINE XR AND 
SERTRALINE IN A MANAGED 
CARE POPULATION
Pinto LA1, Wang SW1, Shen Y2, Wiener D1, Armstrong E3
1Health Benchmarks Inc, Woodland Hills, CA; 2Organon Inc, 
West Orange, NJ; 3University of Arizona, Tucson, AZ
OBJECTIVE: To compare the depression-related health
care expenditures among patients receiving mirtazapine,
venlafaxine XR and sertraline in a managed care setting.
METHODS: Pharmacy and medical claims were ob-
tained for patients in three major health plans, for three
months prior to and six months after their initiation of
antidepressant therapy. Patients included in the study
were 18 years or older; had a primary diagnosis of de-
pression; had no depression-related costs in the pre-index
period; had at least two prescriptions for the study anti-
depressant in the post-index period; were continuously
eligible during the study period, and had no claims for
substance abuse, schizophrenia or bipolar disorder. Cost
comparisons were estimated using multivariate regres-
sions after controlling for demographic and plan charac-
teristics.
RESULTS: Median depression-related costs after index
date for patients prescribed mirtazapine (n  182), ven-
lafaxine XR (n  469) and sertraline (n  4617) were
$344, $374, and $326, respectively. Treatment with ven-
lafaxine XR was associated with 11% higher (p  0.025)
total costs compared to treatment with mirtazapine.
There was no statistically significant difference in total
depression-related costs between mirtazapine and sertra-
line (p  0.072). Similar results were obtained when
pharmacy costs were used as a dependent variable in the
multivariate model.
CONCLUSIONS: Compared to sertraline and mirtazapine,
venlafaxine XR was associated with significantly higher
depression-related total costs. Treatment with mirtazapine
was associated with higher depression-related total costs,
but the results were not statistically significant.
PMH12
THE COST OF TREATING SCHIZOPHRENIA IN 
ROUTINE CLINICAL PRACTICE: RESULTS FROM 
THE CANADIAN NATIONAL OUTCOMES 
MEASUREMENT STUDY IN 
SCHIZOPHRENIA (CNOMSS)
Trakas K1, Lin D2, Balshaw R2, Robinson K1, Andrew E1
1Janssen-Ortho Inc, Toronto, ON, Canada; 2Syreon 
Corporation, Vancouver, BC, Canada
OBJECTIVE: Schizophrenia costs between $CDN 1.17 to
2.94 billion, annually. The objective of this analysis was
to quantify the costs of treatment for patients receiving
clozapine (CLZ), olanzapine (OLZ), quetiapine (QUE) or
risperidone (RIS) as antipsychotic monotherapy.
METHODS: CNOMSS is a prospective, longitudinal,
naturalistic study involving 456 patients from 32 com-
munity and academic sites across Canada. Patients com-
pleted a monthly resource-use questionnaire detailing the
quantity of health-care resources accessed during the pre-
vious month. This study included 316 patients (67 CLZ,
118 OLZ, 28 QUE, 103 RIS) who had used an atypical
antipsychotic as continuous monotherapy since entry
into the study. Each patient’s mean monthly cost of care
was determined. Analysis of covariance was used to com-
pare costs, adjusting for demographic and disease-spe-
cific factors.
RESULTS: The unadjusted cost of care per patient-
month was $2,305 for CLZ, $1,046 for OLZ, $644 for
QUE, and $533 for RIS. Inpatient costs were the greatest
contributors to total costs for CLZ (51%) and QUE pa-
tients (43%), while outpatient costs comprised the great-
est portion of OLZ (34%) and RIS (44%) treatment
costs. From the model, drug costs were higher in CLZ
($415, p  .001) and OLZ patients ($314, p  .001) ver-
sus RIS-treated patients ($145). No difference in drug
costs was detected between RIS and QUE ($160, p 
0.632). Adjusted lab/diagnostic costs (p  .001), psychi-
atric day care (p  0.013), psychiatric nursing (p 
0.001), specialists (p  0.031), and inpatient costs (p 
0.005) were greater in CLZ patients versus RIS-treated
patients. Compared to RIS, the adjusted cost of accessing
social workers was also greater for both CLZ (p 
0.003) and OLZ (p  0.091) patients.
CONCLUSION: The results of this analysis indicate that,
even after adjustment for demographics and severity,
treatment with clozapine is the most costly atypical
monotherapy, while from a budgetary perspective, ris-
peridone was the least expensive drug treatment.
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THE DIRECT COST OF RISPERIDONE VERSUS 
HALOPERIDOL THERAPY FOR CHRONIC 
SCHIZOPHRENIA IN POLAND
Niewada MP1, Kamiñski B2, Splawiñski J3
1Medical University of Warsaw, Warsaw, Poland; 2Warsaw 
School of Economics, Warsaw, Poland; 3Drug Institute, 
Warsaw, Poland.
OBJECTIVE: The novel antipsychotics in comparison
with old ones turned out to have similar clinical efficacy,
produce less adverse effects, increase quality of life, re-
duce hospital stay with subsequent shift in resources to-
wards community care. However, in Poland drug costs
result in substantial percentage of direct health care costs
and cost-effectiveness of novel antipsychotics can be
questionable. A decision analysis model was used to eval-
uate potential clinical and economic consequences of us-
ing oral risperidone versus haloperidol in chronic schizo-
phrenic Polish patients.
METHODS: A decision analysis model based on a three
month Markov cycle tree was implemented through a
time horizon of five years. The probability parameters for
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the model (relapse rates, drop-out rates, switching to
other antipsychotics, adverse effects and other transition
probabilities) were obtained from literature. The clinical
management pattern and cost of therapy in various
model states reflected treatment practice for Polish schizo-
phrenic patients. The model was directed by clinical
guidelines issued in 1997 and adjusted to current clinical
practice. The costs, calculated from the sum of the
charges applicable to each of the management situations
over time, were expressed in 2000 PPP USD values. Boot-
strapping technique was used to evaluate the 95% CI for
mean cost of therapy with both alternative drugs.
RESULTS: The model revealed 11% higher lower relapse
among risperidone patients as compared with haloperi-
dol patients. The mean cost of therapy with risperidone
equaled 11,412 USD. First line treatment with haloperi-
dol resulted in average cost of 11,154 USD. The differ-
ence between both therapies tested by bootstrapping
techniques was not statistically significant.
CONCLUSION: The therapy costs with risperidone and
haloperidol are comparable in Polish clinical and eco-
nomic settings. Higher clinical effectiveness of risperi-
done produces savings, thereby balancing drug cost.
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ANTIPSYCHOTIC COMPLIANCE EVALUATION 
— A POPULATION-BASED, MANAGED-CARE 
STUDY OF PERSISTENCE WITH INITIALLY 
PRESCRIBED ANTIPSYCHOTIC MEDICATION
Simons WR1, Bassi R1, White R2
1Global Health Economics and Outcomes Research, Inc, Short 
Hills, NJ, USA; 2AstraZeneca, Wilmington, DE, USA
OBJECTIVE: To evaluate whether 6-, 9-, and 12-month
rates of persistency (long-term compliance) with initially
prescribed antipsychotic monotherapy translate into cost
savings.
METHODS: We identified 220 newly diagnosed psy-
chotic patients from approximately 180 managed care
organizations who were initiated on quetiapine mono-
therapy during an 18-month period. Patients were ran-
domly selected and matched by study date to populate
three comparator groups: a haloperidol group; a risperi-
done group, and patients initiated on any atypical agent
except quetiapine. Patients were tracked for at least one
year to identify whether they remained on monotherapy,
added to the therapy, switched, or discontinued it. Psy-
chiatric costs were aggregated by service type. Analyses
included tests of proportions for rates, Cox proportional
hazard models for time, and linear regressions for cost.
RESULTS: At six months, 62.73% of quetiapine patients
remained on monotherapy vs 33.51% of haloperidol pa-
tients (p  .01), 44.60% of risperidone patients (p 
.01), and 41.57% of the composite cohort (p  .01). At
nine months, 47.73% of quetiapine patients remained on
monotherapy vs 23.71% of haloperidol patients (p 
.01), 38.97% of risperidone patients (p  0.06), and
32.78% of the composite cohort (p  .01). At one year,
35.45% of quetiapine patients remained on monotherapy
vs 13.40% of haloperidol patients (p  .01), 31.46% of
risperidone patients (p  0.37), and 26.13% of the com-
posite cohort (p  0.01). All three comparisons were sta-
tistically different; median values were 220 days for que-
tiapine, 90 for haloperidol (p  .01), 159 for risperidone
(p  0.02), and 141 for the composite cohort (p  .01).
Annual costs were reduced by $4.39 per additional day
(p  .01) of persistency with the initially prescribed anti-
psychotic. Combining multivariate results shows cost
savings for quetiapine of $570.70/year per patient com-
pared with haloperidol, $250.23/year per patient com-
pared with risperidone, and $307.30 if quetiapine were
the atypical antipsychotic of first choice.
CONCLUSION: When quetiapine is the first-line thera-
peutic choice, more patients remain compliant, and cost
savings result.
PMH15
THE IMPACT OF ALCOHOL ABUSE ON 
EMPLOYMENT IN SWITZERLAND
Chevrou-Severac H
Institute for Economic and Regional Research (IRER), 
Neuchatel, Switzerland
OBJECTIVE: The purpose of this article is to assess the
impact of alcohol abuse on employment in Switzerland.
We used the database from the Swiss Health Survey 1997
to determine the incidence of excessive alcohol consump-
tion on unemployment and productivity at work. To
date, it would appear that this data has never yet been
used in order to analyze such a link.
METHODS: Our approach to the impact of alcohol
abuse on unemployment is traditional and resorts to a
probit model of the probability of being unemployed ac-
cording to variables relating to health and socio-eco-
nomic status. On the other hand, we consider that alco-
hol consumption can have a different impact on income
depending on consumption thresholds. To determine
these thresholds, we adopted the approach by Tsay
(1989) that implies the convergence of the recursive Stu-
dent-t statistics of the estimated coefficient related to the
variable “ALCOHOL” if the model is linear. If this is not
the case, the model possesses two or more regimes (deter-
mined by ruptures of the recursive t).
RESULTS and CONCLUSION: Concerning unemploy-
ment, and for men and women alike, a very high con-
sumption of alcohol has a positive impact on the proba-
bility of becoming unemployed. Regarding the effect of
alcohol consumption on earnings, we find the same re-
sults as the majority of authors, but with a multiple re-
gimes model. Thus, for men, the daily consumption of at
most one glass of an alcoholic drink has a positive impact
on their income. Beyond this quantity the effects are null,
but two sub-regimes are detected with different specifica-
tions. For women, alcohol consumption has a positive ef-
fect on their salary below 2.5 alcohol units per day, and
has no effect beyond this.
